By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449



Company News
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM 4/21/2017 11:09:13 AM
VBL Therapeutics (VBLX) Announces Second Quarter 2016 Financial Results And Provides Business Update 8/15/2016 11:57:52 AM
ASCO2016: VBL Therapeutics (VBLX) VB-111 Clinical Data Presented At ASCO Demonstrate Significant Increase In Overall Survival In Platinum-Resistant Ovarian Cancer 6/6/2016 3:49:08 PM
Newly Granted U.S. Composition Of Matter Patent Extends Exclusive Protection For VBL Therapeutics (VBLX)' Lead Drug Candidate VB-111 Until October 2033 12/1/2015 7:29:44 AM
VBL Therapeutics (VBLX) Announces Significant Improvement Of 12 Month Overall Survival With VB-111 Compared To Pooled Data From Four Avastin Studies At The Annual Meeting Of The Society For Neuro-Oncology 11/19/2015 7:50:09 AM
VBL Therapeutics (VBLX) Data On VB-111 In Combination With Bevacizumab To Be Presented At The Annual Meeting Of The Society For Neuro-Oncology 11/16/2015 7:46:19 AM
VBL Therapeutics (VBLX) Announces Third Quarter 2015 Financial Results And Provides Business Update 11/12/2015 7:25:54 AM
VBL Therapeutics (VBLX) To Report Third Quarter 2015 Financial Results On November 12 11/5/2015 10:08:06 AM
VBL Therapeutics (VBLX) Presents Positive Data On VB-111 In Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer At The ITC 2015 Conference 10/22/2015 7:33:16 AM
VBL Therapeutics (VBLX) Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The ECC 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival 9/28/2015 6:29:27 AM